Drug Profile
Acimtamig - Affimed Therapeutics
Alternative Names: AFM-13; Anti-CD30 anti-CD16A antibody - Affimed Therapeutics; CD30/CD16A; CD30/CD16A ICE®; TandAb AFM13Latest Information Update: 16 Feb 2024
Price :
$50
*
At a glance
- Originator Affimed Therapeutics
- Developer Affimed Therapeutics; The Leukemia & Lymphoma Society; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cutaneous T-cell lymphoma; Hodgkin's disease; Mycosis fungoides; Peripheral T-cell lymphoma
- Phase I/II Anaplastic large cell lymphoma; Non-Hodgkin's lymphoma
Most Recent Events
- 11 Jan 2024 Affimed Therapeutics completes the phase II REDIRECT trial in Peripheral t-cell lymphoma and Mycosis fungoides (Second-line therapy or greater) in USA, Spain, Australia, France, Germany, Italy, South Korea, Poland, Russian and Turkey (NCT04101331) (EudraCT2019-001003-20)
- 11 Dec 2023 Efficacy and adverse events data from a phase I/II trial in Hodgkin lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 14 Nov 2023 Affimed Therapeutics held a type C meeting with the US FDA